The estimated Net Worth of Lorenzo Pellegrini is at least $10.4 Milion dollars as of 7 July 2014. Lorenzo Pellegrini owns over 737,500 units of Minerva Neurosciences Inc stock worth over $10,368,176 and over the last 10 years Lorenzo sold NERV stock worth over $0.
Lorenzo has made over 1 trades of the Minerva Neurosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Lorenzo bought 737,500 units of NERV stock worth $4,425,000 on 7 July 2014.
The largest trade Lorenzo's ever made was buying 737,500 units of Minerva Neurosciences Inc stock on 7 July 2014 worth over $4,425,000. On average, Lorenzo trades about 737,500 units every 0 days since 2014. As of 7 July 2014 Lorenzo still owns at least 3,883,212 units of Minerva Neurosciences Inc stock.
You can see the complete history of Lorenzo Pellegrini stock trades at the bottom of the page.
Lorenzo's mailing address filed with the SEC is C/O MINERVA NEUROSCIENCES, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE, MA, 02142.
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over $49,043,620 worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth $47,876,311 . The most active insiders traders include & Johnson Johnson & Johnson..., Venture Associates Iii Ltd ... oraz Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $556,476. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth $105,193.
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include: